Effects of Epirubicin combined with Oxaliplatin and Fluorouracil transcatheter arterial chemoembolization on patients with primary liver cancer
Objective:To observe effects of Epirubicin combined with Oxaliplatin and Fluorouracil transcatheter arterial chemoembolization on patients with primary liver cancer.Methods:A prospective study was conducted on 122 patients with primary liver cancer admitted to this hospital from January 2021 to January 2023.According to the random number table method,they were divided into study group and control group,61 cases in each group.The control group was treated with Oxaliplatin combined with Fluorouracil transcatheter arterial chemoembolization,while the study group was treated with Epirubicin hydrochloride for injection for transcatheter arterial chemoembolization on the basis of the control group.The objective response rate(ORR),the serum tumor markers[spondin 2(SPON2),carcinoembryonic antigen]levels,the serum liver function indexes[alanine aminotransferase(ALT),total bilirubin,albumin]levels,the Karnofsky performance status score,and the incidence of adverse reactions were compared between the two groups.Results:The ORR of the study group was 86.89%,which was significantly higher than 72.13%of the control group,and the difference was statistically significant(P<0.05).After 8 weeks of treatment,the serum albumin level and the Karnofsky performance status score of the study group were higher than those of the control group,the serum carcinoembryonic antigen,SPON2,total bilirubin and ALT levels were lower than those of the control group,and the differences were statistically significant(P<0.05).There were no significant differences in the incidence of adverse reactions such as nausea and vomiting,alopecia and leukopenia between the two groups(P>0.05).Conclusions:Epirubicin combined with Oxaliplatin and Fluorouracil transcatheter arterial chemoembolization for the patients with primary liver cancer can improve the ORR,the Karnofsky performance status scores and the serum albumin levels and reduce the serum carcinoembryonic antigen,SPON2,total bilirubin and ALT levels.Moreover,it is superior to single Oxaliplatin combined with Fluorouracil transcatheter arterial chemoembolization.
EpirubicinOxaliplatinFluorouracilTranscatheter arterial chemoembolizationPrimary liver cancerTumor markerLiver function
NETL
NSTL
万方数据
